Accelerating development of next-generation cancer testing using 3D cell culture technology within the Texas Medical Center, the largest and most efficient life sciences ecosystem in the world.
Accelerating development of next-generation cancer testing using 3D cell culture technology within the Texas Medical Center, the largest and most efficient life sciences ecosystem in the world.
Tokyo, Japan, April 4, 2026 -- TOPPAN Holdings Inc. (TYO: 7911) (TOPPAN Holdings) has established a new company, TOPPAN Global Medical Healthcare Inc., in Houston, Texas, to advance its personalized cancer medicine and drug discovery support businesses.
By establishing a base in Helix Park’s TMC3 Collaborative Building, a commercial life sciences and innovation hub within the Texas Medical Center, the company gains direct access to TMC’s dense network of cancer research, clinical facilities, and patient populations. TOPPAN Holdings aims to accelerate research and development and support the real-world implementation of personalized cancer medicine using its proprietary invivoid™ 3D cell culture technology.
Background
In modern cancer treatment, there is a rapidly growing global demand for "personalized medicine," which selects the most effective therapies and drugs for each individual patient. In July 2025, TOPPAN Holdings entered into a strategic alliance with The University of Texas MD Anderson Cancer Center to co-develop clinical tools that evaluate treatment efficacy using patient-derived samples.
The newly established company will serve as a strategic headquarters to directly manage collaborations with local medical institutions and pharmaceutical companies in the United States, the world's largest healthcare market.
Objectives
TOPPAN Global Medical Healthcare will focus on the following key areas:
1. Acceleration of clinical validation: Deepen joint research with UT MD Anderson to expedite clinical validation studies across several cancer types and work toward obtaining College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) certification.
2. Expansion of drug discovery support: Contribute to accelerating and enhancing new drug development by providing major U.S. pharmaceutical companies with an efficient drug screening environment utilizing invivoid™.
3. Establishment of a global network: Leverage Houston’s position as a hub of medical innovation to incorporate cutting-edge knowledge, top-tier talent, and connections with research institutions into global business development.
Overview of the New Company
- Trade name: TOPPAN Global Medical Healthcare Inc.
- Location: TMC3 Collaborative Bldg., 7255 Helix Park Ave., Suite 300, Houston, TX 77030, USA
- Date of establishment: March 2026
- Capital: US$ 2.0 million (approx. 290 million JPY)
- Main shareholder: TOPPAN Holdings Inc. (100%)
- Representative: Shiro Kitano, President/CEO
- Business activities: Personalized cancer medicine support and drug discovery support using invivoid™ 3D cell culture technology
Future Activities
Through TOPPAN Global Medical Healthcare, TOPPAN Holdings will build a track record of clinical success in the United States and contribute to a society where optimal medical care is delivered to every cancer patient. TOPPAN Holdings has positioned the medical and healthcare field as a core pillar of growth and will continue to aggressively expand its business on a global scale.
About invivoid™ 3D Cell Culture Technology
invivoid™ is TOPPAN Holdings’ proprietary 3D cell culture technology, developed through joint research with the University of Osaka. It enables the simple and rapid creation of artificial tissues that closely mimic living organisms.
- Rapid model construction: Capable of establishing "cancer organoids" (mini-cancers) from a minute amount of patient biopsy tissue within just a few days.
- Optimal treatment selection: Allows for testing multiple drug types before actual administration to identify the most effective treatment for each patient, helping to avoid unnecessary side effects and treatment delays.
- High reproducibility: Accurately reproduces the complex microenvironments found within the human body using unique biomaterials, such as specialized coating agents.
For more information on invivoid™: https://www.holdings.toppan.com/en/invivoid/index.html
About the TOPPAN Group
Established in Tokyo in 1900, the TOPPAN Group is a leading and diversified global provider committed to delivering sustainable, integrated solutions in fields including printing, communications, security, packaging, décor materials, electronics, and digital transformation. The TOPPAN Group’s global team of more than 50,000 employees offers optimal solutions enabled by industry-leading expertise and technologies to address the diverse challenges of every business sector and society and contribute to the achievement of shared sustainability goals.
https://www.holdings.toppan.com/en/
https://www.linkedin.com/company/toppan/
If there are any deficiencies, problems, or concerns regarding the information presented in this press release that require attention or if you need assistance with a press release takedown, we encourage you to notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our diligent team is committed to promptly addressing your concerns within 8 hours and taking necessary actions to rectify any identified issues or facilitate the removal process. Providing accurate and trustworthy information is of utmost importance.
